Treatment dilemmas in patients with synchronous colorectal liver metastases

Recent Results in Cancer Research

Volumn 196, Issue , 2012, Pages 37-49

  Ruers, T J M ^a   Hagendoorn, J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; DISEASE FREE SURVIVAL; HUMAN; INDIVIDUALIZATION; INTESTINAL BLEEDING; INTESTINE OBSTRUCTION; LIVER METASTASIS; LIVER RESECTION; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEPSIS; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SYMPTOM; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 84870033360     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-31629-6_3     Document Type: Article

References (58)

1. Adam R (2007) Colorectal cancer with synchronous liver metastases. Br J Surg 94: 129-131
2. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240: 1052-1061
3. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M, Castagne V, Azoulay D, Castaing D (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25: 4593-4602
4. Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, Ledermann JA, O'Bichere A (2009) Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol 35 (2): 164-167
5. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE (1981) Natural history of untreated patients with liver metastases from colorectal cancer. Am J Surg 141: 586-589
6. Benoist S, Pautrat K, Mitry E et al (2005) Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 92: 1155-1160
7. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945
8. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26: 5344-5351
9. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20: 1759-1766
10. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M (2008) Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15: 219-226
11. Damjanov N, Weiss J, Haller DG (2009) Resection of the primary colorectal cancer is not necessary in nonobstructed patients with metastatic disease. Oncologist 14: 963-969
12. De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8: 393-404
13. de Jong MC, van Dam RM, Maas M, Bemelmans MH, Olde Damink SW, Beets GL, Dejong CH (2011) The liver-first approach for synchronous colorectal liver metastasis: a 5 year singlecentre experience. HPB (Oxford) 13: 745-52
14. Eisenberger A, Whelan RL, Neugut AI (2008) Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis 23: 559-568
15. Evans MD, Escofet X, Karandikar SS, Stamatakis JD (2009) Outcomes of resection and nonresection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol 7:28
16. Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M et al (2008) First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg 143: 352-358
17. Giacchi R, Sebastiani M, Lungarotti F (1988) Natural history of synchronous hepatic metastases from a non-treated colorectal cancer. J Chir 125: 419-423
18. Grothey A, Sargent D (2005) Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol %20;23: 9441-42
19. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
20. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
21. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23: 3706-3712
22. Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P et al (2008) Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 15: 3440-3446
23. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27: 3677-3683
24. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA (2012) Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 255: 237-247
25. Lo SS, Moffatt-Bruce S, Dawson LA, Schwarz RE, The BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD (2011) The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 8: 405-416
26. Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O (2001) Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 78: 17-21
27. Mella J, Biffin A, Radcliffe AG et al (1997) Population-based audit of colorectal cancer management in two UK health regions. Colorectal cancer working group, Royal college of surgeons of England clinical epidemiology and audit unit. Br J Surg 84: 1731-1736
28. Mentha G, Roth AD, Terraz S, Giostra E, Gervaz P, Andres A, Morel P, Rubbia-Brandt L, Majno PE (2008) 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 25: 430-435
29. Michel P, Roque I, Di FF et al (2004) Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol 28: 434-437
30. Millikan KW, Staren ED, Doolas A (1997) Invasive therapy of metastatic colorectal cancer to the liver. Surg Clin North Am 77: 27-48
31. Muratore A, Zorzi D, Bouzari H et al (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14: 766-770
32. O'Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425
33. Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ (2004) Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer 112: 554-559
34. Peeters CF et al (2005) Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 137: 246-249
35. Peeters CF, De Waal RM, Wobbes T, Westphal JR, Ruers TJ (2006) Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer 119: 1249-1253
36. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG et al (2009) Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 27: 3379-3384
37. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, Barbas AS, Abdalla EK, Choti MA, Vauthey JN, Ludwig KA, Mantyh CR, Morse MA, Clary BM (2007) Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 14: 3481-3491
38. Ruo L, Gougoutas C, Paty PB et al (2003) Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg 196: 722-728
39. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK et al (2008) Fiveyear data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26: 5721-5727
40. Sarela A, O'Riordain DS (2001) Rectal adenocarcinoma with liver metastases: management of the primary tumour. Br J Surg 88: 163-164
41. Schmidt C (2009) Metastatic colorectal cancer: is surgery necessary? J Natl Cancer Inst 101: 1113-1115
42. Scoggins CR, Meszoely IM, Blanke CD et al (1999) Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 6: 651-657
43. Scheithauer W, Kornek GV, Raderer M, Schoell B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21: 1307-1312
44. Scheer MG, Sloots CE, van der Wilt GJ, Ruers TJ (2008) Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. Ann Oncol 19 (11): 1829-35. (Epub 28 Jul 2008, Review)
45. Shields AF, Zalupski MM, Marshall JL, Meropol NJ (2004) Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 100: 531-537
46. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94: 982-999
47. Stillwell AP, Buettner PG, Ho YH (2010) Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 34 (4): 797-807
48. Tebbutt NC, Norman AR, Cunningham D et al (2003) Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 52: 568-573
49. Thelen A, Jonas S, Benckert C, Spinelli A, Lopez-Hänninen E, Rudolph B, Neumann U, Neuhaus P (2007) Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis 22: 1269-1276
50. Turrini O, Viret F, Guiramand J, Lelong B, Bège T, Delpero JR (2007) Strategies for the treatment of synchronous liver metastasis. Eur J Surg Oncol 33: 735-740
51. van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C (2010) Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg 97: 383-390
52. Van Dijk TH, Havenga K, Beukema J, Beets GL, Gelderblom H, de Jong KP, Rutten HJ, Van De Velde CJ, Wiggers T, Hospers G (2010) Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: a phase II multicenter study of the Dutch colorectal cancer group. ASCO Meeting Abstract: J Clin Oncol 28:15s (suppl; abstr 3638)
53. Vassiliou I, Arkadopoulos N, Theodosopoulos T, Fragulidis G, Marinis A, Kondi-Paphiti A, Samanides L, Polydorou A, Gennatas C, Voros D, Smyrniotis V (2007) Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations. World J Gastroenterol 13: 1431-1434
54. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH (2009) The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 52: 23-30
55. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilson DM (1984) The natural history of hepatic metastases from colorectal cancer. Ann Surg 199: 205-208
56. Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D (2003) Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 90: 956-962
57. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145-147
58. Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2: 285-288